Venrock healthcare survey shows pessimism on drug pricing
Skepticism remains high that the drug pricing debate will lead to action despite the FDA vowing to combat high drug prices. That was one of the findings in a survey of 300 healthcare experts conducted by the venture firm Venrock. A majority of those polled said that they believe there will still be more talk than action on prescription drug prices, with 19 percent believing that nothing will happen with prescription drug prices.
25 April 2018•1 min read
